ArticleTranslational pediatrics2026
Predictors of using biologics within one year after EEN therapy in pediatric Crohn's disease.
Article in Translational pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Biologics are commonly used as the second-line medication for maintenance of remission after exclusive enteral nutrition (EEN) induction in pediatric Crohn's disease (CD). However, predictors of using biologics after EEN therapy in CD are yet to be elucidated. This study explores the predictive factors for the application of biologics in children with CD who had finished 8 weeks of EEN induction. Methods: Seventy-five patients were divided into derivation group (n=54) and validation group (n=21). Baseline characteristics were compared between biological group and non-biological group. Univariate and multivariate analyses were performed to correlate 102 laboratory indicators. Finally, binary stepwise logistic regression was used to construct a prediction model. Results: The predictor identified for biologic use in the prediction model was complement C4 and red blood cell distribution width (RDW). Complement C4 [odds ratio (OR) =1.04, 95% confidence interval (CI): 1.01-1.07] and RDW (OR =1.41, 95% CI: 1.05-1.91) were identified as significant independent predictors (P<0.05). Patients with baseline complement C4 levels >0.415 g/L and RDW >13.5% were more likely to use biologics within 1 year after EEN. Conclusions: Complement C4 and RDW are predictors of biologic use within 1 year after EEN-induced clinical remission. Elevated complement C4 and RDW are associated with the use of biologics after induction of remission. However, extensive experimental validation is still required to confirm the above findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.